大股东持续反对 盟科药业定增易主折戟

Core Viewpoint - Mengke Pharmaceutical's planned private placement has been terminated after facing significant opposition from major shareholders and board members, despite initial approval from the shareholders' meeting [1][3][6]. Group 1: Termination of Private Placement - Mengke Pharmaceutical announced the termination of its plan to issue 164 million shares to Nanjing Haijing Pharmaceutical Co., Ltd., which was intended to raise 1.033 billion yuan for daily R&D and operational investments [3]. - The termination was influenced by ongoing disagreements between major shareholder Genie Pharma and the company's management, leading to concerns about the potential impact on the company's stable operations [3][4]. - The company will negotiate with Haijing Pharmaceutical regarding the termination of related agreements and will fulfill its information disclosure obligations as progress occurs [3]. Group 2: Opposition from Shareholders - The private placement faced early opposition from board members and major shareholders, with board member Zhao Yachao voting against the proposal, citing a lack of thorough investigation and the absence of synergistic benefits with Haijing Pharmaceutical [4]. - Genie Pharma, as the largest shareholder, expressed concerns about the financial implications of the deal, particularly regarding Haijing's debt levels and the potential impact on control stability [5][6]. - Despite the initial approval from the shareholders' meeting, Genie Pharma did not receive any proxy votes from other shareholders, indicating a lack of support for the private placement [5]. Group 3: Financial Performance - Mengke Pharmaceutical has not yet achieved profitability, but it reported a reduction in net losses due to the market penetration of its core product, Kantizolam [6]. - For the first three quarters of the year, the company generated approximately 104 million yuan in revenue, reflecting a year-on-year increase of 6.58%, while the net loss attributable to shareholders was about 194 million yuan, an improvement from a loss of 291 million yuan in the same period last year [6].